Top Markets
Coin of the day
Gracell Biotechnologies Inc. Gracell Biotechnologies Inc.

Gracell Biotechnologies Inc.

GRCL
Peringkat dalam Saham #20199
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company... Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China. The company's leading investigational therapies include: GC012F: A FasTCAR-enhanced autologous CAR-T product designed to target both BCMA and CD19, currently undergoing Phase I clinical trials for multiple myeloma. GC019F: A FasTCAR-enabled CD19-directed autologous CAR-T therapy, which is progressing through Phase I trials for adult B-cell acute lymphoblastic leukemia (B-ALL) and is also in preclinical development for relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL). GC027: A TruUCAR-powered allogeneic CAR-T product targeting CD7, presently in Phase I clinical development for adult T-cell acute lymphoblastic leukemia. Additionally, Gracell's pipeline features: GC007g: A donor-derived allogeneic CAR-T cell therapy directed at CD19, currently in a Phase 1/2 registrational study for r/r B-ALL. GC502: An off-the-shelf, TruUCAR-enabled allogeneic CAR-T candidate engineered to target both CD19 and CD7, which is in Phase I trials for B-cell malignancies. Beyond these, Gracell maintains a broader portfolio of earlier-stage therapeutic candidates addressing diverse oncological conditions, including ovarian cancer, breast cancer, peripheral T cell lymphoma (a subtype of NHL), and T cell lymphoblastic leukemia. Established in 2017, the company's headquarters are situated in Suzhou, China.
Harga Saham
$10.25
Terakhir disinkronkan: 2024-02-22
Kapitalisasi Pasar
$137.83M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
CN
Perdagangan Gracell Biotechnologies Inc. (GRCL)

Kategori

EPS untuk Gracell Biotechnologies Inc. (GRCL)
EPS per 2026 TTM: 0
Menurut laporan keuangan terbaru dan harga saham Gracell Biotechnologies Inc., EPS perusahaan saat ini (TTM) adalah 0. Pada akhir 2026, perusahaan memiliki EPS sebesar 0 sama dengan EPS tahun 2026 sebesar 0.
Riwayat EPS untuk Gracell Biotechnologies Inc. dari 2026 hingga 2026
EPS di akhir setiap tahun
Tahun EPS Mengubah
Tidak cukup data untuk tanggal yang disediakan.
EPS untuk perusahaan sejenis atau pesaing
Perusahaan EPS Perbedaan EPS Negara
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH